Related Articles
Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report
Apatinib combined with trastuzumab and albumin‑bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti‑HER2 TKIs: A case report
Long‑responders to anti‑HER2 therapies: A case report and review of the literature
Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report
Multiple metastases of human epidermal growth factor receptor 2‑positive, hormone receptor‑positive, pT1a pN0 breast cancer within 1 year after surgery: A case report